logo-loader
viewAntibe Therapeutics, Inc.

Antibe Therapeutics running largest number of sites for any clinical trial in Canada in ATB-346 study

Total enrollment in its Phase 2B study recently surpassed 70% and patient recruitment has accelerated

clinical trial
An ongoing Phase 2B study is looking at the effectiveness of the drug in reducing osteoarthritis pain in 360 patients

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) updated shareholders Thursday on the progress of its study on its lead drug ATB-346, a novel painkiller being developed as an alternative to currently available opioids. 

The Toronto-based company’s ongoing Phase 2B study is looking at the effectiveness of the drug in reducing osteoarthritis pain in 360 patients. 

The biotech company is now running the largest number of sites for any clinical trial conducted in Canada after activating an additional five sites recently, bringing the total number of clinical sites to 40. 

Total enrollment recently surpassed 70% and patient recruitment has accelerated, Antibe told shareholders.

READ: Antibe Therapeutics is ready for a big push as it progresses pain management drug through clinical trials

CEO Dan Legault said the company was “pleased” with the conduct of the study despite slower enrollment than initially anticipated.

“We’ve taken extra measures to expedite the completion of enrollment, but with the inevitable slowdown during the holiday season, we are pushing our guidance for top-line data to calendar Q1 2020,” Legault said in a statement.

The firm told investors that it is making headway on a number of fronts as it progresses ATB-346 towards commercialization, including preparation for global partnerships with pharmaceutical companies, securing a contract manufacturing organization and rebranding its corporate website.

It reported a cash balance of C$8 million at the end of September and subsequently raised an additional C$1.3 million through the exercising of warrants.

Antibe also issued a total of 7,630,000 restricted share units to directors, officers, employees and consultants as part of its shareholder plan.

In addition to the US, Antibe also said it was pursuing regulatory approval in Europe for ATB-346.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Antibe Therapeutics, Inc.

Price: 0.405 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $111.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics, Inc. named herein, including the promotion by the Company of Antibe Therapeutics, Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibe Therapeutics is looking to the future after successful past year

Antibe Therapeutics  (CVE:ATE-OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from the Proactive Investors Toronto studio to discuss his recent letter to the shareholders in which he outlined the company’s last year. Legault also talked about the year ahead and the prep work they...

on 4/7/19

2 min read